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Pemphigus foliaceus (PF) and the endemic form Fogo Selvagem (FS) are mediated by pathogenic antibodies to the
EC1–2 domains of desmoglein-1. There is a preclinical phase with antibodies to only EC5. Based on geographic
clustering of cases, FS is thought to have an, as yet unidentiﬁed, environmental trigger. In this study we have
searched for anti-desmoglein-1 antibodies in sera from parasitic (leishmaniasis, Chagas, and onchocerciasis), and
infectious diseases (leprosy and South American (SA) blastomycosis), which are prevalent in the same geographic
regions of Brazil as FS. A specific and sensitive desmoglein-1 ELISA detected antibodies in 34 of 41 onchocerciasis
(83%), 38 of 88 leishmaniasis (43%), 18 of 31 Chagas disease (58%), 7 of 28 SA blastomycosis (25%), and 14 of 83
leprosy sera (17%). These sera recognized epitopes restricted to the EC5 domain. These ﬁndings identify several
etiological factors for FS. It is hypothesized that a component of insect vector saliva, rather than the parasite itself
may trigger an antibody response to EC-5. In persons with the known HLA susceptibility alleles and living in
endemic areas, a response to the EC1–2 domains may subsequently develop by epitope spreading with associated
clinical signs of FS.
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Both endemic (fogo selvagem (FS)) and non-endemic pe-
mphigus foliaceus (PF) are characterized by subcorneal
epidermal blisters and autoantibodies against desmoglein-1
(Dsg1) (Stanley et al, 1986; Diaz et al, 1989a). These auto-
antibodies are predominantly of the IgG4 subclass and
pathogenic as demonstrated by passive transfer studies in
neonatal mice (Roscoe et al, 1985; Rock et al, 1989). FS
patients usually live in impoverished rural areas of certain
states of Brazil where the disease is endemic (Paes–Leme,
1903; Vieira, 1937). Endemic PF has also been described in
Colombia and Tunisia (Robledo et al, 1988; Morini et al,
1993). The disease exhibits a strong association with the
HLA-DRB10404, 1402, or 1406 alleles (po0.005, RR: 14)
(Moraes et al, 1997) and affects people of many races and
ethnic backgrounds who live in endemic areas. Strikingly,
the prevalence of FS in some states, e.g. Sao Paulo, has
decreased dramatically in recent years (Diaz et al, 1989b).
Additionally, a hospital case–control study previously
showed that exposure to simuliid bites was 4.7 times more
frequent in individuals developing FS than in those not ex-
posed to bites (Lombardi et al, 1992). It is thought that a
local environmental agent or agents acting on genetically
predisposed individuals triggers a pathogenic anti-Dsg1
antibody response that leads to FS.
We have identified a new focus of FS in the Amerindian
Terena reservation of Limao Verde, Brazil, where the prev-
alence of the disease is 3.4% (Hans-Filho et al, 1996). We
have reported previously that 30 of 31 patients along with
55% of normal subjects (n¼93) living in this reservation
possessed anti-Dsg1 antibodies (Warren et al, 2000). A
case–control study conducted in this reservation suggested
that the presence of hematophagous insects in patient
homes might be a relevant risk factor for FS (Aoki et al,
2004). Moreover, Simulium nigrimanum (Eaton et al, 1998),
Cimex hemipterus, Triatoma matogrossensis, and T. sordida
have been identified in this reservation (D. Eaton et al, un-
published data). Neither Trypanosoma cruzi nor filarial par-
asites were identified by microscopic examination of these
arthropods. Interestingly, although cutaneous leishmaniasis
is prevalent in Limao Verde, Chagas disease and onc-
hocerciasis are not, despite the presence of the arthropod
vectors in this settlement.
Based on these observations, we hypothesized that an
antigen(s) from blood feeding insects (simuliids, phleboto-
Abbreviations: Dsg, desmoglein; FS, fogo selvagem; PF, pe-
mphigus foliaceus; SA, South American
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mines, or triatomines) might trigger antibody formation in
humans resulting in cross-reactive antibodies to epidermal
Dsg1. Testing for disease-specific and cross-reactive anti-
bodies against arthropod antigen(s) among the inhabitants
of Limao Verde is problematic because not only FS patients,
but also a significant number of normal individuals of this
community possess anti-Dsg1 antibodies (Warren et al,
2000). To overcome this difficulty, we have searched for
anti-Dsg1 antibodies in patients with tropical parasitic dis-
eases where hematophagous vectors, found in Limao
Verde, are involved in the transmission of illness, i.e. onc-
hocerciasis (black flies), leishmaniasis (sand flies), and Cha-
gas disease (kissing bugs). The Dsg1 reactivity of this group
was compared with patients with infectious diseases (in
which insect vectors are not involved) such as leprosy and
South American (SA) blastomycosis, and a group of normal
controls from Brazil and USA.
Results
The sera of patients with onchocerciasis, leishmaniasis,
and Chagas disease recognize Dsg1 and its EC5 do-
main All FS/PF sera tested were positive (100% of 40)
whereas all normal human sera from the USA were negative
(100% of 57) by Dsg1-ELISA (Fig 1). This figure shows that
the groups with the greater percentage of positive sera, aside
from the FS/non-endemic PF group, were from patients with
parasitic diseases such as onchocerciasis (83% of 41 test-
ed), Chagas disease (58% of 31 tested), and leishmaniasis
(43% of the 88 tested). Interestingly, the leishmaniasis groups
from Brazil (73% of the 30 tested), Peru (31% of the 36 test-
ed), and other parts of the world (36% of the 22 tested) were
significantly different (p¼0.0015) (Table I).
In the infectious disease group, we found seven of the 28
SA blastomycosis sera (25%) and 14 of the 83 leprosy sera
(17%) tested also reacted with Dsg1. Leprosy sera from
Brazil exhibited a higher percentage of positive samples
(24% of 37 samples) than samples from Mexico (12.1% of
33 samples) or other parts of the world (8% of 13 samples),
but these differences were not statistically significant
(p¼0.3) (Table I). The prevelance of antibodies directed
against Dsg1 in sera from the onchocerciasis, leishmania,
and Chagas groups was significantly higher (po0.001) than
the estimated true prevalance in this population of 20%
previously reported by Warren et al (2000). In contrast, the
sera from the SA Blastomycosis and leprosy group did not
show a significant increase in prevalence above this esti-
mated true prevalence.
We used immunoprecipitation as a second assay to
detect the presence of anti-Dsg1 antibodies in the sera of
onchocerciasis, leishmaniasis, and Chagas disease. The
sera of these patients were tested using the full-length
ectodomain of Dsg1. Dsg1 was detected using a mono-
clonal antibody against histidine residues that had been
engineered into the recombinant protein. The results are
summarized in Table II. Representative results of the
immunoprecipitation studies depicted in Fig 2 show that
90% of the onchocerciasis sera (n¼42), 80% of the le-
ishmaniasis sera (n¼89), and 55% of the Chagas sera
(n¼36) were capable of immunoprecipitating Dsg1. Ninety-
five percent of the USA normal human sera tested (n¼39)
yielded negative results. There were two samples in this
group that yielded a weakly positive reaction. Six bullous
pemphigoid sera produced negative results.
For epitope-mapping studies, we selected sera from
onchocerciasis (n¼ 15), leishmaniasis (n¼ 11), and Chagas
(n¼6) that produced distinct positive reactions with the
Figure1
Desmoglein (Dsg)1-ELISA. A significant
number of sera from patients with onc-
hocerciasis, leishmaniasis, and Chagas
possess anti-Dsg1 antibodies. The fol-
lowing data are given: number of positive/
total (No.), % of positive sera, 95% con-
fidence interval (CI), and the p-value. The
p-value is the probability of observing
prevalence similar to that actually ob-
served, or higher, if the true prevalence
were actually 20%. FS, Fogo Selvagem;
PF, non-endemic pemphigus foliaceus;
SA, South American; NHS, normal human
serum from USA; CO, cut-off value.
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full-length Dsg1 ectodomain by immunoprecipitation as-
says. Four recombinant proteins were used, which included
the full-length ectodomain of Dsg1, the EC1-4 domains, the
EC5 domain, and the full-length ectodomain of Dsg3 (see
Fig 3). Figure 4 shows representative examples of these
studies. All onchocerciasis (n¼15), leishmaniasis (n¼ 11),
and Chagas (n¼ 6) sera recognized the EC5 domain of
Dsg1. Six onchocerciasis sera and three leishmaniasis sera
weakly recognized the EC4 domain of Dsg1. This group of
sera reacted weakly with the EC1–4 construct, but did not
react with the EC1–3 construct (data not shown). None of
the sera tested reacted with the full-length Dsg3 ectodo-
main (the backbone molecule used to produce these
recombinant Dsg1 hybrid proteins).
Reactivity of FS and control sera with trypanosoma,
leishmania, and ﬁlarial antigens The sera of patients with
FS (n¼ 20), normal controls from Limao Verde (with and
without anti-Dsg1 antibodies) (n¼10), and non-endemic PF
from the USA (n¼ 5) were tested at Centers for Disease
Control and Prevention (CDC) for antibodies against T. cruzi
and leishmania by indirect immunofluorescence techniques.
None of these sera reacted with the parasite antigens. Sim-
ilarly, a group of 20 sera from FS patients tested by indirect
immunofluorescence and ELISA techniques at the Univer-
sity of Sao Paulo, Brazil produced negative results using
T. cruzi and leishmania antigens.
Fifty-four percent of sera from inhabitants of Limao Verde
(n¼ 30) possessed antibodies against a crude extract of
filarial antigens (values above 13.5 mg per mL, which rep-
resents 3 SD above the mean of uninfected normal individ-
uals); however, the prevalence of anti-filarial antibodies in
the FS group (nine of 18) and the Limao Verde normal con-
trol group (six of ten) was similar. Moreover, anti-filarial
antibodies in these sera were independent of anti-Dsg1
Table I. Desmoglein-1 (Dsg1) ELISA results in leishmaniasis
and leprosy sera from patients of different countries
Leishmaniasisa Leprosyb
Brazil 22/30 (73%) 9/37 (24%)
Peru 11/36 (31%) NA
Me´xico NA 4/33 (12%)
Other parts of the worldc 8/22 (36%) 1/13 (8%)
aLeishmania groups from Brazil, Peru, and other parts of the world
were significantly different, p¼ 0.0015.
bLeprosy groups from Brazil, Mexico, and other parts of the world were
not significantly different, p¼ 0.3; NA, not available.
cCDC samples.
Table II. Summary of immunoprecipitation results for anti-desmoglein-1 (Dsg1) antibodies
Reactions
Onchocerciasis Leishmaniasis Chagas Normal sera (USA) Bullous Pemphigoid
Number (n¼42) % Number (n¼ 89) % Number (n¼ 36) % Number (n¼39) % Number (n¼ 6) %
Positive 32 76 51 57 7 19 0 0 0 0
Weak positive 6 14 20 23 13 36 2 5 0 0
Negative 4 10 18 20 16 44 37 95 6 100
Figure2
Detection of anti-desmoglein (Dsg)1 antibodies by immunoprecip-
itation assays. Each panel contains immunoprecipitates produced by
a well-characterized strong fogo selvagem (FS) serum (1:400 dilution)
(lane A), a weak FS serum (1:100 dilution) (lane B), and a USA normal
human serum (1:100 dilution) (lane C). Lanes 1–10 of each panel con-
tain serum samples (1:100 dilution) from onchocerciasis, leishmaniasis,
and Chagas disease, respectively. The molecular weight is shown on
the left of each panel. An arrow on the right of each panel shows the
location of Dsg1. FS serum A (lane A) shows strong positive staining in
all panels. FS serum B (lane B) shows good staining of Dsg1. Normal
human serum C (lane C) shows no reactivity. Serum #1 of panel I
(onchocerciasis) shows weak positive staining, whereas sera 2–10
show good positive staining of Dsg1. Sera #1–8 of panel II (le-
ishmaniasis) show good positive staining; whereas, sera #9 and 10
show negative staining. Serum #1 of panel III (Chagas) shows good
positive staining; sera 2–9 show weak positive staining, whereas serum
#10 is negative.
ANTIBODIES TO DSG1 IN SEVERAL TROPICAL CUTANEOUS DISEASES 1047123 : 6 DECEMBER 2004
antibodies (data not shown). Five sera from non-endemic
PF showed low titers of anti-filarial antibodies (less than 6.3
mg per mL).
Discussion
This investigation demonstrated that a significant number of
patients with parasitic diseases such as onchocerciasis,
leishmaniasis, and Chagas disease possess anti-Dsg1 an-
tibodies in their sera when tested against the full-length
ectodomain of Dsg1 using both highly specific and sensitive
ELISA and immunoprecipitation assays. Importantly, none
of these patients showed evidence of skin disease sugges-
tive of FS. The control sera, which include normal human
donors from the USA and patients with bullous pemphigoid,
yielded negative tests for anti-Dsg1 antibodies, demon-
strating the specificity of our assays.
The results shown in Fig 1 and Table II demonstrate that
over 80% of the onchocerciasis sera possess anti-Dsg1
antibodies by these two assays (83% of 41 tested by ELISA
and 91% of 42 tested by immunoprecipitation). Similarly,
over 50% of the Chagas sera exhibited anti-Dsg1 antibod-
ies (58% of 31 tested by ELISA and 55% of 36 tested by
immunoprecipitation). In the leishmaniasis group the ELISA
assay detected 43% of positive sera in a large cluster of
sera (n¼88) from Brazil, Peru, and CDC; whereas, by
immunoprecipitation, 80% of the same sera showed pos-
itive results. The ELISA results of the leishmaniasis group
showed substantial differences in the number of positive
sera in donors from Brazil (73% of 30 tested) as compared
with donors from Peru (31% of 36 tested) and other parts of
the world (36% of 22 sera tested), (p¼0.0015) (Table I).
Other groups that showed lower reactivity with Dsg1 by
ELISA comprised patients with tropical infectious diseases
such as SA blastomycosis (25% of 28) and leprosy (17% of
83). The differences in percent positive tests between Bra-
zilian leprosy patients (24% of 37), patients from Mexico
(12% of 33), or other parts of the world (8% of 13) were not
statistically significant (p¼0.3) (Table I). Since FS is en-
demic to the same Brazilian regions from where the le-
ishmaniasis, SA blastomycosis, and leprosy sera were
collected, these intriguing results suggest a shared envi-
ronmental antigen(s) triggering anti-Dsg1 antibody produc-
tion in these patients.
If the background prevalence of anti-Dsg1 antibodies
in endemic areas of FS is 20% (Warren, 2000) the high
prevalence of these antibodies in patients with parasitic
diseases (onchocerciasis, leishmaniasis, and Chagas) is
significant (po0.001).
Epitope mapping studies using a representative number
of positive sera of each group (15 onchocerciasis, 11 le-
ishmaniasis, and six Chagas) and recombinant fragments of
the Dsg1 ectodomain and the full-length Dsg3 ectodomain
revealed that all samples tested from onchocerciasis, le-
ishmaniasis, and Chagas disease recognized the EC5
Figure 3
Molecular structures of desmoglein (Dsg)1, Dsg3, and chimeric
antigens. The top panel shows the molecular structures of Dsg1 and
Dsg3. The cell membrane (labeled CM) and the N and C terminal of
each molecule are as depicted. Each ectodomain of the molecule
contains five domains labeled EC1, EC2, EC3, EC4, and EC5. The
degree of sequence identity between each domain of Dsg1 (white) and
Dsg3 (gray) are indicated. The EC5 domains of these molecules exhibit
no significant homology (NS). The black strips represent Ca2þ binding
motifs. The bottom panel shows the domain structure of the three chi-
meras of Dsg1 and Dsg3 used in this investigation. The Dsg1 (1–3)
chimera spans domains 1–3 of the Dsg1 molecule (shown in white); the
Dsg1 (1–4) chimera spans domains 1–4 of Dsg1 and chimera Dsg1 (5)
contains domain 5 of Dsg1 only. A six-histidine tag (H) was attached to
the C-terminus of the recombinant proteins.
Figure4
Epitope mapping studies of anti-desmoglein (Dsg)1 antibodies
from representative onchocerciasis, leishmaniasis, and Chagas
sera. The full-length ectodomains of Dsg3 (lane 1) and Dsg1 (lane 2),
the hybrid proteins containing the EC1–4 domain (lane 3) and the EC5
(lane 4) domain of Dsg1 were used in immunoprecipitation procedures.
All sera recognized the EC5 domain of Dsg1. The 15 sera from onc-
hocerciasis, 11 from leishmaniasis, and six from Chagas disease did
not react with Dsg3. Additionally, six onchocerciasis sera bound weakly
the EC4 domain of Dsg1 (data not shown).
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domain of Dsg1 (Fig 4). Importantly, none of these sera
recognized Dsg3, which is another indicator of the spe-
cificity of the immunoprecipitation assay in detecting anti-
Dsg1 antibodies. Li et al (2003) have recently demonstrated
that the EC5 domain is also recognized by sera from normal
individuals from Limao Verde (exhibiting anti-Dsg1 anti-
bodies) and FS patients during the preclinical stage
of the disease. They hypothesized that this domain might
contain the initial epitope(s) that trigger(s) the autoimmune
response in FS.
The presence of anti-Dsg1 antibodies specific for the
EC5 domain in patients with vector-mediated parasitic dis-
eases implies immunization with an environmental EC5-
cross-reactive antigen(s). The present studies suggest that
these cross-reactive antigen(s) may originate from the in-
sect vector(s) of onchocerciasis, leishmaniasis, and Chagas
disease themselves. In addition to their own sensitizing
products (e.g. saliva), however, these vectors carry para-
sites that cause the respective diseases. Importantly, FS
sera did not recognize trypanosoma or leishmania antigens.
Unexpectedly, we found that 50% of the sera from Limao
Verde (patients and controls) recognized filarial antigens by
an ELISA assay using crude filarial antigens; however, the
prevalence of anti-filarial antibodies in sera from FS patients
and controls was independent of the presence of anti-Dsg1
antibody titers by indirect immunofluorescence and/or
ELISA. The low specificity of the assay (Lal and Ottesen,
1988) and the high prevalence of non-filarial intestinal par-
asites in the Limao Verde population (unpublished data)
may explain these findings.
Another source(s) of sensitizing antigen(s) leading to anti-
Dsg1 response in onchocerciasis, leishmaniasis, and Cha-
gas disease might be the saliva of the hematophagous
vector, which is known to induce antibody responses in
humans (Barral et al, 2000). Interestingly, the genome of the
fruit fly Drosophila melanogaster contains 18 cadherin
family member proteins, which bear structural similarities
to human Dsg1 (Hill et al, 2001) suggesting that hemato-
phagous vectors may similarly possess numerous cadherin
family members in their structural or secreted proteins. It is
unclear whether the sensitizing antigen(s) is the same in all
three vectors (simuliids, phlebotomines, or triatomines) or
whether they represent different molecules sharing the
same Dsg1 cross-reactive epitope. It is also important to
consider that individuals living in these endemic regions are
usually exposed simultaneously to all three arthropod bites.
These individuals may develop the respective tropical dis-
ease (leishmaniasis, Chagas, onchocerciasis), but may ad-
ditionally exhibit antibodies to the other vectors to which
they were exposed. Therefore, each disease group may
possess anti-Dsg1 antibodies produced in response to an
antigen(s) from a single vector or from all three arthropods.
In conclusion, if arthropod bites trigger a non-pathogenic
anti-Dsg1 antibody response in humans, this phenomenon
would likely be common to other parts of the world where
individuals are similarly exposed to these vectors. The rarity
of FS and its unique epidemiological features, such as the
clustering of cases in certain endemic regions of Brazil, re-
quire further explanation. Based on the present findings and
recent studies by Li et al, we propose that an arthropod
salivary antigen(s) triggers an early antibody response that
cross-reacts with the EC5 domain of Dsg1 by molecular
mimicry (Oldstone, 1987). Since these anti-EC5 antibodies
are non-pathogenic the majority of these individuals remain
disease-free. Only a small minority of subjects, those that
will develop FS, might extend their immune response by
epitope spreading (Lehmann et al, 1993; Li et al, 2003) to
include pathogenic antibodies against the EC1 and EC2
domains of Dsg1. Additionally, the autoimmune disease in
these patients may be perpetuated by continuous exposure
to self-Dsg1. The high prevalence of FS in Limao Verde may
have resulted from inbreeding of the population resulting
in a large number of genetically predisposed individuals
who are repeatedly exposed to a sensitizing agent(s).
Experimental confirmation of this hypothesis may have im-
portant implications in understanding human autoimmune
disease.
Materials and Methods
Sources of sera for assaying anti-Dsg1 antibodies Several
groups of sera were tested: (a) This set comprised samples ob-
tained from patients with parasitic diseases where an insect vector
transmits the parasite that causes the illness. This group included
sera from patients with onchocerciasis (n¼ 42), leishmaniasis
(n¼ 89), and Chagas disease (n¼ 36). Twenty-nine sera from pa-
tients with leishmaniasis (23 cutaneous and six mucocutaneous)
and 31 from Chagas disease were obtained from the Department
of Dermatology of the University of Sao Paulo (USP), Brazil. These
patients originated from the State of Sao Paulo and neighboring
states and had no cutaneous signs of FS. The diagnosis of leish-
maniasis and Chagas disease was confirmed by histological
examination, indirect immunofluorescence, and ELISA assays.
Other well-characterized sera from 25 patients with leishmaniasis
from different continents and countries (Central America, n¼ 10;
Middle East and Asia, n¼ 6; Europe, n¼ 2; South America, n¼ 4;
USA, n¼ 1; unknown, n¼ 2) and five patients with Chagas disease
were obtained from the Division of Parasitology, Centers for Dis-
ease Control and Prevention (CDC), Atlanta. Additionally, we
obtained 35 serum samples from leishmaniasis patients (31
mucocutaneous form and four cutaneous) from the laboratory of
Dr Antunez de Mayolo from Lima, Peru, and 42 sera from onc-
hocerciasis patients (18 from Guatemala and 24 from Africa) from
the laboratory of Dr Nutman, National Institute of Allergy and
Infectious Diseases (NIAID), Bethesda, Mary Land.
(b) Another group of sera was obtained from patients with trop-
ical infectious diseases such as SA blastomycosis (n¼ 28) and
leprosy (n¼ 83). The 28 SA blastomycosis sera and 37 of the lep-
rosy sera were also obtained from the Department of Dermatology
USP, Brazil. Forty-six leprosy sera (33 from Mexican patients and
13 from other countries) were supplied by Dr Thomas Rea from the
LAC-USC Medical Center, Los Angeles, California. The diagnosis
of SA blastomycosis was established by clinical, histological, and
mycological criteria.
(c) The third group contained sera from USA normal individuals
(n¼ 57). To assess the background prevalence of anti-Dsg1
antibodies in a normal Brazilian population, we use previously
published ELISA data (Warren, 2000). Briefly, in this study we found
that out of 279 normal individuals living outside of Limao Verde
(high prevalence of FS), 54 possessed anti-Dsg1 antibodies
(20%). This 20% background prevalence of anti-Dsg1 antibod-
ies, 18 of 96, has also been recently found in Parana, another
Brazilian region where FS is endemic (Empinotti, unpublished
data).
(d) The specificity of the immunological assays was also tested
using sera from patients with bullous pemphigoid (n¼ 6) from
the USA containing antibodies against two antigens, BP230 and
BP180 (Giudice and Diaz, 1996).
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Other sera tested for antibodies against leishmania, trypano-
soma, and ﬁlarial antigens We also sent well-characterized sera
to the following laboratories: (a) CDC, for assaying antibodies
against T. cruzi (Chagas disease parasite) and leishmania (le-
ishmaniasis parasite) antigens: FS (n¼ 10), non-endemic PF
(n¼ 5), and sera from normal individuals (n¼ 10) from Limao Verde
containing anti-Dsg1 antibodies (Warren et al, 2000). The sera were
tested against T. cruzi (epimastigote stage from a Brazilian strain)
and leishmania (promastigote stage, WHO-DD8 from India) by in-
direct immunofluorescence techniques. (b) Dr Nutman at the NIAD:
for assaying antibodies against filarial antigens (onchocerciasis
parasite): FS sera from Limao Verde (n¼ 20), non-endemic PF from
USA (n¼ 5), normal donors from Limao Verde showing anti-Dsg1
antibodies (n¼ 5), and normal donors from Limao Verde exhibiting
negative anti-Dsg1 serology (n¼ 5). Anti-filarial antibodies by an
ELISA assay at the laboratory of NIAID using a PBS-soluble extract
of Brugia malayi (Hamilton et al, 1981). (c) Finally, a set of 20 well-
characterized sera from FS patients seen at the University of Sao
Paulo were also tested for antibodies against antigens from T. cruzi
and leishmania sp. by commercially available indirect immunoflu-
orescence and ELISA techniques (Immunocruzi, Biolab, Hemobio,
Embrabio and Institute Adolfo Lutz from Sao Paulo, Brazil).
The sera were kept frozen at 201C and transported from Bra-
zil, Peru, CDC, and NIAID to our laboratory at UNC following CDC
regulations. Each group of sera was anonymized by code following
their arrival in our laboratory. All described studies had the ap-
proval of the IRB at University of North Carolina, and the study was
conducted according to the Declaration of Helsinki Principles.
Construction and production of recombinant Dsg1, Dsg3, and
chimeric antigens The desmosomal cadherins Dsg1 and Dsg3
are targets of pathogenic antibodies in patients with the two dis-
tinct autoimmune diseases non-endemic PF (and FS) and pe-
mphigus vulgaris, respectively (Udey and Stanley, 1999). As shown
in Fig 3 (top), the ectodomains of Dsg1 and Dsg3 have extensive
sequence homology. We have constructed and expressed in the
baculovirus system the entire extracellular domains of human Dsg1
and Dsg3 (Ding et al, 1997, 1999). Recently, we have engineered
and expressed in baculovirus eight hybrid molecules of Dsg1 and
Dsg3 (Li et al, 2003) in which the ectodomains of the two antigens
were swapped as has been described by others (Netzer et al,
1999; Sekiguchi et al, 2001). Three of these hybrid molecules (EC1-
3, EC1-4, and EC5) were chosen for epitope-mapping studies
(Fig 3, bottom). All the recombinant proteins were histidine tagged
at the C-terminal of the molecule.
ELISA assays We used a Dsg1-ELISA assay as previously re-
ported (Warren et al, 2000; Arteaga et al, 2002) with the following
modifications. Purified histidine-tagged recombinant Dsg1 was
used to coat the nickel-NTA plates (Qiagen, Valencia, California) at
50 ng per well. Patient or normal subject sera were added to the
coated plate in duplicate at a dilution of 1:200 in TBS-Ca2þ buffer,
pH 7.2, containing 1% BSA and 0.05% Tween 20. The plate was
then incubated with HRP-mouse monoclonal anti-human IgG
(Zymed Lab, San Francisco, California) diluted to 1:1000 in TBS-
Ca2þ pH 7.2/1% BSA/0.05% Tween 20. The same positive and
negative controls were used in duplicate on each ELISA plate.
Duplicate ELISA results were averaged. An ELISA index value was
obtained as follows: [(test resultnegative control)/(positive con-
trolnegative control)  100]. A cut-off value was established as a
value 2.5 SD above the mean of the 57 normal donors from the
USA. Several sera generated negative values after subtraction of
background and correction for plate-to-plate variability, as their OD
value was below the negative control.
Statistical analysis The confidence intervals and tests for bino-
mial proportions were based on exact binomial calculations. The p-
values in Fig 1 were based on testing the null hypothesis that the
true prevalence of positives (background prevalence for people
living in endemic areas of FS in Brazil, outside Limao Verde) is 20%
(Warren, 2000) against the alternative that it is greater than 20%.
Other tests for proportions were two sided and based on Fisher’s
exact test.
Immunoprecipitation assays Recombinant Dsg1 (0.5 mg) was
immunoprecipatated with each test serum (0.5 mL) using a protocol
as previously reported (Li et al, 2003). Two sera from FS patients (A,
B) and one from a USA normal human donor (C) were used
throughout as controls. Serum A showed an indirect immunoflu-
orescence titer of 1:640, serum B a titer of 1:20, and serum C was
negative. The three control sera (A, B, and C) and 10 test sera were
processed simultaneously in each experiment. Serum A was tested
at a 1:400 dilution; whereas, serum B and normal human serum at
a dilution of 1:100.
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